"BACKGROUND INFORMATION FOR THE PEDIATRIC SUBCOMMITTEE OF THE ONCOLOGIC DRUGS ADVISORY COMMITTEE MEETING 04 DECEMBER 2012", 4 December 2012 (2012-12-04), XP055203294, Retrieved from the Internet <URL:http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM330210.pdf> [retrieved on 20150717] (B1)

DIRK NAGORSEN ET AL: "Blinatumomab: A historical perspective", PHARMACOLOGY & THERAPEUTICS, vol. 136, no. 3, 1 December 2012 (2012-12-01), pages 334 - 342, XP055112692, ISSN: 0163-7258, DOI: 10.1016/j.pharmthera.2012.07.013 (B1)

VISSER J H ET AL: "Prognostic value of day 14 blast percentage and the absolute blast index in bone marrow of children with acute lymphoblastic leukemia", PEDIATRIC HEMATOLOGY AND ONCOLOGY, TAYLOR AND FRANCIS, GB, vol. 18, no. 3, 1 January 2001 (2001-01-01), pages 187 - 191, XP008177028, ISSN: 0888-0018, DOI: 10.1080/08880010151114804 (B1)

G. TALLEN ET AL: "Long-Term Outcome in Children With Relapsed Acute Lymphoblastic Leukemia After Time-Point and Site-of-Relapse Stratification and Intensified Short-Course Multidrug Chemotherapy: Results of Trial ALL-REZ BFM 90", JOURNAL OF CLINICAL ONCOLOGY, vol. 28, no. 14, 12 April 2010 (2010-04-12), pages 2339 - 2347, XP055203293, ISSN: 0732-183X, DOI: 10.1200/JCO.2009.25.1983 (B1)

JAN STARY ET AL: "Results of the Randomized I-BFM-SG Trial "Acute Lymphoblastic Leukemia Intercontinental-BFM 2002" in 5060 Children Diagnosed in 15 Countries on 3 Continents", 18 September 2011 (2011-09-18), pages 397 - 398, XP055203224, Retrieved from the Internet <URL:https://ash.confex.com/ash/2011/webprogram/Paper40820.html> [retrieved on 20150717] (B1)

G. BASSO ET AL: "Risk of Relapse of Childhood Acute Lymphoblastic Leukemia Is Predicted By Flow Cytometric Measurement of Residual Disease on Day 15 Bone Marrow", JOURNAL OF CLINICAL ONCOLOGY, vol. 27, no. 31, 5 October 2009 (2009-10-05), pages 5168 - 5174, XP055203226, ISSN: 0732-183X, DOI: 10.1200/JCO.2008.20.8934 (B1)